No Data
No Data
CRISPR Therapeutics AG (NASDAQ:CRSP) Is Largely Controlled by Institutional Shareholders Who Own 73% of the Company
'Incoming Regulatory Tailwinds' to Spur 90% Upside for CRISPR Therapeutics Stock, Says BMO Capital
BMO Capital Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Maintains Target Price $97
BofA Securities Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Cuts Target Price to $80
CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade
Crispr Therapeutics AG (CRSP) Receives a Buy From Bank of America Securities